Compare THFF & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | THFF | PHAR |
|---|---|---|
| Founded | 1984 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 930.9M | 793.4M |
| IPO Year | 1995 | 2020 |
| Metric | THFF | PHAR |
|---|---|---|
| Price | $76.04 | $10.92 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $62.00 | $38.33 |
| AVG Volume (30 Days) | ★ 86.1K | 17.0K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.46% | N/A |
| EPS Growth | ★ 67.00 | N/A |
| EPS | ★ 3.58 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.88 | $10.04 |
| Revenue Next Year | $4.03 | $2.51 |
| P/E Ratio | ★ $21.53 | $3,041.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $51.21 | $9.62 |
| 52 Week High | $84.17 | $21.34 |
| Indicator | THFF | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 35.09 | 40.01 |
| Support Level | $74.32 | $9.62 |
| Resistance Level | $78.57 | $13.51 |
| Average True Range (ATR) | 1.75 | 0.38 |
| MACD | -0.26 | -0.04 |
| Stochastic Oscillator | 23.28 | 12.79 |
First Financial Corp operates as a financial holding company, which is engaged in the provision of financial services in the United States. The company offers a wide variety of financial services including commercial, mortgage, and consumer lending, lease financing, trust account services, depositor services and insurance services, through its subsidiaries. Its primary source of revenue is derived from loans to customers and investment activities. Company's loan portfolio was diversified in Commercial, Residential and consumer domains.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.